Neogenomics (NEO) Total Non-Current Liabilities (2012 - 2026)

Neogenomics (NEO) has 15 years of Total Non-Current Liabilities data on file, last reported at $460.6 million in Q2 2026.

• Quarterly Total Non-Current Liabilities rose 4.74% year-over-year to $460.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $460.6 million (up 4.74% YoY) and the FY2025 annual result came in at $435.0 million, changed 0.12% from the prior year.
• Total Non-Current Liabilities rose to $460.6 million in Q2 2026, from $433.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $672.5 million in Q1 2022 to a low of $433.2 million in Q1 2026.
• A 5-year average of $545.0 million and a median of $549.3 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities rose 15.36% — and 2024, when it plunged 32.47%.
• Tracing NEO's Total Non-Current Liabilities over 5 years: stood at $652.1 million in 2022, then decreased by 1.33% to $643.4 million in 2023, then sank by 32.47% to $434.5 million in 2024, then advanced by 0.12% to $435.0 million in 2025, then climbed by 5.9% to $460.6 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $460.6 million (Q2 2026), $433.2 million (Q1 2026), and $435.0 million (Q4 2025), per Business Quant data.